Pharma Focus Asia
KP - Choose our fully recyclable blister films

A Novel Oral Therapy Discovered to Treat Adult Patients with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Blueprint Medicines Corporation discovered GAVRETO™ for the treatment of adult patients with metastatic Rearranged during Transfection (RET) fusion-positive Non-small Cell Lung Cancer (NSCLC).

GAVRETO an oral, RET-targeted therapy is taken daily twice. The oral therapy is designed to selectively and potently inhibit RET alterations which gives rise to many types of cancers, including approximately 1 to 2 percent of patients with NSCLC.

GAVRETO™ oral therapy makes a potential benefit in changing standards of care for patients with RET fusion-positive non-small cell lung cancer, where the treatments for patients are limited.

Some of the major side effects with GAVRETO include interstitial lung disease/pneumonitis, hypertension, hepatotoxicity, hemorrhagic events, risk of impaired wound healing and risk of embryo-fetal toxicity.

U.S. Food and Drug Administration (FDA) has approved GAVRETO™ (pralsetinib) for the treatment of adult patients with metastatic RET fusion-positive Non-small Cell Lung Cancer (NSCLC).

Latest Issue
Get instant
access to our latest e-book
THERMOFISHER SEACertara - Is your drug program on trackMasterControl - Manufacturing demoMasterControl - QMS demoThermo Fisher Scientific - Rapid Mycoplasma TestingThermoFisher Scientific - Save costs on your downstream process todayMerck - Mobius® productsThermo Fisher Scientific - Peptones5th Annual Pharma Manufacturing and Automation Convention 2023DUPHAT 202410TH ANNUAL GCC PHARMACY CONGRESS 2023Reuters Events - Pharma Customer Engagement USA 202314th Annual Emirates Cardiac Society Conference 2023The International Hand & Wrist Congress 2023LabAsia 2023Pharma & Patient USA 2023Pharma Customer Engagement Europe 2023CHEMICAL INDONESIA 2024INALAB 2024